Journal of the American Academy of Child & Adolescent Psychiatry
Volume 44, Issue 8 , Pages 829-832, August 2005

Pharmacological Management of Agitation and Aggression in an Adolescent With Autism

Dr. Kratochvil is with the Department of Psychiatry, University of Nebraska Medical Center, Omaha; Dr. Findling is with the Departments of Psychiatry and Pediatrics, University Hospitals of Cleveland/Case Western Reserve University, Cleveland; Dr. McDougle is with the Department of Psychiatry, Indiana University School of Medicine, Indianapolis; Dr. Scahill is with the Yale Child Study Center, Yale University, Hartford, CT; Dr. Hamarman is with the Stanley S. Lamm Institute for Child Neurology and Developmental Medicine and Downstate Medical School, State University of New York, New York

Accepted 28 March 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Dr. Kratochvil is supported by grant 5K23MH06612701A1 from the National Institute of Mental Health.Based on a topic suggested by Derek Richardson, M.D., and Martin Drell, M.D. Case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration (FDA). We fully appreciate that for virtually all disorders medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil has received grant support from or been a consultant and/or member of a speaker's bureau for Eli Lilly, GlaxoSmithKline, Forest, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Findling receives or has received research support from or been a consultant and/or member of a speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pfizer, Shire, Solvay, and Wyeth. Dr. McDougle has received grant support from or been a consultant and/or member of a speaker's bureau for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceutical, PediaMed Pharmaceuticals, and Pfizer. Dr. Scahill has consulted for Janssen Pharmaceutical, Pfizer, and Bristol-Myers Squibb. Dr. Hamarman has received grant support from or been a consultant and/or member of a speaker's bureau for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceutical, McNeil, Orphan Medical, and UCB-Pharma.

PII: S0890-8567(09)61745-7

doi:10.1097/01.chi.0000166380.68392.4b

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 44, Issue 8 , Pages 829-832, August 2005

Article Tools